						-T	Complete 'CY'							
Substitute for form 1449/PTO (Revised 07/2007)							Application Number 10/599,448							
								umo	er	10/599,448				
							ling Date			03/08/2007				
INFORMATION DISCLOSURE							First Named Inventor			Pascal Drevet				
STATEMENT BY APPLICANT							Art Unit			1648				
(Use as many sheets as necessary)							Examiner Name			Stuart Snyder				
Sheet	1 of 1						Attorney Docket Number			033339/317269				
	·				U	. S. I	PATENT D	OCU	JMENT	S	*******			
		Document Number								David Calum				
Examiner Initials*	Cite No.	- 1	Nun	ımber - Kind Code (if known)			Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns Relevant Passag			
initials 1		o. Trained - Kind Code (ii known)			10110	IVIIVI-DD-1111		- spendant of Citou Document		Figures Appear				
		US-												
		US-												
										·····				
US-														
	FOREIGN PATENT DOCUMENTS													
P	O'4-		Foreign Patent Document						NCD		Pages, Columns, Lines, Where Relevant Passages or Relevant		English	
Examiner Initials	Cite No.		Country Code - Number Kind Code			le	Publication Dat		Name of Patentee or Applicant of Cited				Language Translation	
			(if known)						Document		Figures Appear		Attached	
											-			
OTHER DOCUMENTS  English														
				Include name of the author (in item (book, magazine, journal, publisher, city and/or country v			CAPITAL LETTERS), title of the article (when appropriate), titl						Language	
Examiner		Cite						catal	og, etc.), d	late, page(s), volun	e, page(s), volume-issue number(s),		Translation	
Initials*		No.		F								Attached		
		1		L. STEINAA, A.M. SERENSEN, J.O. NIELSEN, and JE.S. HANSEN;										
/SS/				"Antibody to HIV-1 Tat protein inhibits the replication of virus in culture";										
8				ARCHIVES OF VIROLOGY; SPRINGER-VERLAG 1994, PRINTED IN									l	
		AUSTRIA; Vol. 139; pag					ges 263-271.							
00000	2 TODD M. ALLEN, ET AL.; "Tat-specific cytotoxic T lymphocytes select for SIV								SIV					
		escape variants during resolution of primary viraemia"; NATURE; Vol. 147;												
	September 21, 2000; pages 386-390.													
		3 ALAIN LECOQ, ET AL.; "Increasing the humoral immunogenic properties of the									the			
2000000				HIV-1 Tat protein using a ligand-stabilizing strategy; VACCINE; 2008; Vol. 26; Pages 2615-2626.										
999999														
		4		SABRINA	TURBANT	ET	AL.: "Cvnor	nolo	us maca	aues immunize	l with two			
XX				SABRINA TURBANT, ET AL.; "Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a										
<b>2000000</b>		pattern of Th1/Th2 re				ponse differing from that in mice; VACCINE; 2009;								
W				doi:10.1016/j.vaccine.2009.06.083.									***************************************	
/O.O.	,	5		"Effect of a heparin fragment (Hep6000) on HIV VPR and Nef Immunogenicity".							v".			
/SS														
Examiner	$\dashv$								Date		00/40	1/2010		
Signature		/Stuart Snyder/							Consid	03/16/2010 lered				

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.